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An increased understanding of the cell biology of keratinocytes allows efficient propagation of these cells in culture 1 and production of enough epidermis to cover the body surface of an average adult owing to sufficient proliferative capacity of the cells.
2 Skin grafting procedures have been established for the clinical treatment of burned patients. 3 These achievements provide the tools to manipulate large amounts of skin cells ex vivo and prepare the ground for skin gene therapy ex vivo.
Skin-directed gene transfer might be used for the treatment of a variety of skin diseases, [4] [5] [6] [7] [8] including acquired disorders such as cancer, burns or chronic non-healing wounds, [9] [10] [11] or inherited diseases such as epidermolysis bullosa, ichthyosis and xeroderma pigmentosum. [12] [13] [14] [15] [16] Moreover, systemic diseases such as adenosine deaminase deficiency, hemophilia A or B, and renal anemia might also be treated by transfer of a relevant therapeutic gene into the skin. 17, 18 For this purpose, a vector has to provide a high transduction efficiency and sustained gene expression. Thus, the stable transduction of keratinocyte stem cells is essential to achieve long-term gene expression in the skin. 19, 20 Until now, retroviral vectors were used in skin gene therapy. They appear to transduce up to 100% of keratinocytes in vitro, including keratinocyte stem cells. 21 An alternative vector thought to offer some additional advantages might be recombinant adeno-associated virus (rAAV). [22] [23] [24] [25] [26] [27] Adeno-associated virus (AAV) is a human, naturally replication defective, non-enveloped parvovirus which does not seem to be pathogenic for human beings. rAAV vectors can now be packaged and purified to high titers. [28] [29] [30] rAAV vectors transduce proliferating cells and non-proliferating cells with high efficiency in vitro. 31, 32 It has been shown in animal models that rAAV is an attractive in vivo gene delivery vehicle. [33] [34] [35] [36] [37] [38] [39] [40] For example, a single injection of rAAV into the muscle of mice resulted in sustained transgene expression for over 1.5 years and did not elicit a cytotoxic T cell response against the virus or the transgene. 33, 37, 41 Moreover, a slight humoral immune response against AAV capsid proteins could be prevented by transient immunosuppression allowing successful repeated administration of rAAV vectors in vivo. rAAV has previously been shown to transduce several epitheloid cell lines efficiently. [43] [44] [45] However, the use of rAAV has not been evaluated in primary human keratinocytes so far. To explore the potential of rAAV for somatic skin gene therapy, we performed a series of experiments in order to define the optimal conditions for efficient gene transfer into primary human keratinocytes in vitro.
Construction and production of rAAV vectors: rAAV/LacZ vector was produced as described previously.
29,45
pAAV/GFP was generated as follows: pAAV/CEP contained two expression cassettes in opposite orientation, flanked by the ITRs of AAV2. The first cassette was composed of the cytomegalovirus immediate-early promoter (CMV), a multiple cloning site for any transgene and a SV40 polyadenylation signal. The second cassette was composed of a hygromycin B resistance gene with a thymidine kinase (TK) promoter (pTK) and a TK polyadenylation signal (TKpA). Both cassettes were derived from the plasmid pCEP4 (Invitrogen, Carlsbad, CA, USA). pAAV/CEP was constructed by turning the first cassette of pCEP4 into the opposite direction by SalI digestion and religation. After partial SalI and NruI digestion, both expression cassettes were subcloned into XbaI-digested psub201, which contained the ITRs. pAAV/GFP was constructed by inserting the Asp718I/NotI fragment from pEGFP-N3 (Clontech, Palo Alto, CA, USA) into the the KpnI/NotI multiple cloning site of pAAV/CEP. The total length of the pAAV/GFP was 4346 bp.
Because the helper plasmid pSV40oriAAV 29,45 contained small sequences in the ITRs which overlapped with the transgene plasmids (pAAV/LacZ or pAAV/GFP), we generated a new helper plasmid, pRC, in which the overlapping sequences between the helper and the transgene plasmids were reduced to a minimum. For this purpose, psub201 (obtained from Jude Samulski, Chapel Hill, NC, USA) was digested with XbaI to isolate the complete AAV2 coding sequence without the ITRs. pRC was generated by ligation of the resulting fragment into pBluescript (Stratagene, Heidelberg, Germany).
Titers of transducing rAAV particles were measured by infecting HeLa cells with limiting dilutions of virus and counting positive cells after 48 h. Virus titers were determined: (1) with unmodified rAAV stocks after density centrifugation; (2) with rAAV stocks which were heat treated for 1 h at 56°C in order to inactivate remaining Ad5 helper virus; and (3) with heat-treated rAAV as above, supplemented with a defined amount of Ad5 (MOI 1). The successful elimination of infectious Ad5 by heat treatment was checked by the absence of any cytopathic effect (CPE) after at least 1 week. Typical transducing rAAV/LacZ particle titers were 1-2 × 10 5 IU/ml after heat treatment, 5 × 10 5 IU/ml with unmodified stocks, and 2 × 10 7 IU/ml after addition of Ad5 (MOI 1) to heattreated stocks. In this article, transducing titers are given as unmodified particles unless indicated otherwise. The 100-to 200-fold increase of rAAV titers after the addition of Ad5 was in accordance with published data. 59, 60 The difference in rAAV/LacZ titers before and after heat treatment was readily explained by a residual Ad5 contamination of 3% in the unmodified rAAV stocks, as demonstrated by dot blot analysis (not shown). rAAV/GFP titers were approximately 10 times higher than rAAV/LacZ titers, probably due to one of the following differences in the two vectors: different promoters, 61 different length of rAAV genomes, 62 or different sensitivity of the detection method for transduced cells. Contamination of rAAV stocks with wild-type AAV as assessed by dot blot analysis was less than 1% of rAAV particles using the helper plasmid pRC, and approximately 10% of rAAV using the helper plasmid pSVori-AAV. For ␤-galactosidase expression, transduction was visualized by X-gal histochemistry as previously published. 49, 55, 63 GFP expression (in Figure 2d in combination with transmission light) was assessed under an Axiovert 135 fluorescence microscope (Zeiss, Oberkochen, Germany) using excitation/emission spectra of 395 and 525 nm (FITC channel), respectively.
Human keratinocytes are efficiently transduced by rAAV in vitro: To investigate whether rAAV vectors transduced human keratinocytes, cells were isolated from human skin samples, seeded on to plastic dishes and transduced with rAAV/LacZ. In order to exclude the transduction of contaminating fibroblasts or melanocytes, the purity of primary keratinocyte cultures was examined by immunocytochemistry using different monoclonal antibodies (mAb) (Figure 1 ). The mAb LP34 recognizes keratins expressed by basal and differentiating keratinocytes, 46 and the mAb Vim 3B4 recognizes vimentin expressed on cells of mesenchymal origin. 47 Figure 1a shows that nearly all cells were stained by the LP34 mAb, indicating that most cells were keratinocytes. In contrast, no cells were stained by the mAb Vim 3B4 (data not shown). A nuclear staining with DAPI was used to identify adherent cells (Figure 1b) . Cells defined as keratinocytes by these parameters were used in all subsequent gene transfer experiments. Figure 2 shows two representative experiments of freshly isolated, human keratinocytes from two different donors which could be efficiently transduced with two different rAAV vectors, rAAV/LacZ and rAAV/GFP, respectively. In the first experiment, keratinocytes isolated from the skin of a middle-aged female patient undergoing mammary reduction surgery were infected with a rAAV/LacZ vector (multiplicity of infection (MOI) 5 IU per cell); X-gal staining was performed 48 h later. As shown in Figure 2a , up to 70% of the keratinocytes were successfully transduced. In contrast, untreated keratinocytes did not show any blue nuclear staining ( Figure  2b ). In the second experiment, keratinocytes derived from the foreskin of a 2-year-old boy were transduced with a rAAV/GFP vector (MOI 2 IU per cell). Forty-eight hours later, up to 50% of the cells showed green fluorescence (Figure 2c and d) . With regard to cell density, optimal conditions for rAAV transduction were achieved with keratinocytes grown to 50-70% confluence. These conditions were reached when cells were plated at a density of 10 000-20 000 cells/cm 2 followed by a growth period of 12-24 h.
Because the transduction efficiency of rAAV vectors may vary among different donors, at least in hematopoietic cells, 48 we performed further experiments with keratinocytes isolated from eight other skin donors. In each case, keratinocytes were transducible with rAAV/LacZ or rAAV/GFP without marked variation in transduction efficiency (data not shown). Since rAAV/LacZ and rAAV/GFP used the RSV and CMV promoter, respectively, to drive the transgene expression, the results also showed that the transduction efficiency was independent of the promoter used.
In an attempt to increase further the transduction efficiency of keratinocytes by rAAV vectors, various conditions known to enhance the transduction of these cells by retrovirus or plasmid vectors were tested. For example, poly-l-ornithine (12 g/ml) and the application of a glycerol shock (15% glycerol for 4 min applied 2 h after transduction) were used. 49, 50 However, both conditions decreased the transduction of keratinocytes by rAAV vectors (data not shown). Other methods known to increase rAAV transduction efficiency, such as hydroxyurea, etoposide or ␥-irradiation, were not tested because they carried the risk of decreasing cell viability and proliferation of keratinocytes 51 and were therefore not useful with regard to clinical applications. Irradiation of keratinocytes with UV light under a cell culture hood at 10 J/m 2 resulted only in a slight increase of transduction efficiency (data not shown). Taken together, these experiments showed that primary human keratinocytes obtained from different donors and body areas could be transduced efficiently by rAAV vectors coding for different reporter genes under the control of two different promoters.
In order to evaluate the relationship between the number of transducing rAAV particles used and transduction efficiency, primary human keratinocytes were transduced with increasing concentrations of rAAV/LacZ (MOI 0.1 to 5.0 IU per cell). X-gal staining was performed after 48 h. As expected, the transduction efficiency increased with the number of transducing rAAV particles used ( Figure  3) . A plateau was reached at a MOI of у2 IU per cell. At rAAV concentrations of 2-5 IU per cell, approximately 70% of cells were stained by X-gal.
Since wild-type AAV has been reported to induce differentiation in the human keratinocyte cell line HaCaT, 44 this raised the concern that rAAV vectors might induce the differentiation of keratinocytes and inhibit their proliferation. To address this question, we first examined the ability of transduced keratinocytes to survive passaging. Keratinocytes were infected with rAAV/LacZ (MOI 1 IU per cell) and split 1:3 2 days later. The percentage of viable cells was determined by trypan blue exclusion on day 4 after transduction and compared with untransduced cells grown under identical conditions. Both transduced and untransduced keratinocyte cultures showed about 10% trypan blue stained cells, indicating that rAAV had only modest, if any effect on keratinocyte viability. In a next series of experiments, we used rAAV/GFP because GFP could be visualized in living cells without prior fixation or incubation with substrates. 52 This allowed us to study whether rAAV-transduced keratinocytes maintained the ability to proliferate and to determine the duration of transgene expression. Fifty thousand keratinocytes were transduced with heat-inactiviated rAAV/GFP (MOI 1 IU per cell), containing less than 1% of wild-type AAV. Cells were further cultivated, passaged twice at 3:1 and replated into fresh dishes. Under these conditions, keratinocytes were able to divide even between day 26 and day 27 after transduction ( Figure 4) . The transduced cells shown in Figure 4 were maintained for up to 35 days in culture.
Next, we examined whether transduced keratinocytes were able to form colonies. For this purpose, keratinocytes were transduced with heat-treated rAAV/GFP (MOI 2 IU per cell) containing less than 1% wild-type AAV, and plated at a density of 100-150 cells/cm 2 onto 70% confluent, ␥-irradiated feeder cells. Interestingly, transduced cells did not grow until they were replated after transduction. It is possible that contaminating wildtype AAV caused this growth arrest in cultured keratinocytes, as was shown previously in human fibroblasts. 53 Figure 5 shows two small cell fluorescent colonies each derived from single, transduced keratinocytes which were apparently transduced by rAAV and expressed the transgene after four to five cell divisions; the photograph was taken on day 5 after the first replating. Thereafter, cells were further passaged, and GFP expression was followed until 7 weeks after infection with rAAV. Some cells continued to show GFP expression up to 50 days after infection with rAAV/GFP. Thereafter, it was not possible to maintain keratinocytes in culture, because cells did not proliferate further and did not adhere after subsequent attempts at replating. Since these cells showed the characteristics of clonal growth, we feel justified in speculating that rAAV is able to transduce keratinocyte stem cells. More sophisticated keratinocyte culture techniques will be required to determine more precisely the efficiency of rAAV in transducing keratinocyte stem cells in vitro.
Taken together, the experiments demonstrate that rAAV is able to mediate long-term expression of the GFP gene in cultured human keratinocytes in vitro. We could also show that rAAV used at a relatively low MOI of 2-5 transduced up to 70% of primary human keratinocytes obtained from specimens of different body areas and different individuals in vitro. Finally, preliminary evidence suggested that rAAV was able to transduce keratinocyte stem cells. Keratinocytes or keratinocyte stem cells, which are the major target cells for skin gene therapy, are usually difficult to transduce. 49 Many different methods have been evaluated for this purpose. Nonviral gene transfer methods including liposome, DEAE-dextran or polycation-mediated transfection were successful in transducing up to 30% of keratinocytes. 49, [54] [55] [56] For long-term gene correction, the major disadvantage of these nonviral methods is transient gene expression. 52 Viral vector systems such as adenovirus or herpes simplex virus were also tested for skin gene transfer, but induced cytotoxicity and necrosis after application to the murine skin in vivo. 57 So far, the best results have been obtained using retroviral vectors, yielding up to 100% transduction efficiency and long-lasting gene expression for over 150 cell divisions in vitro. 21 rAAV vectors equally have the potential for long-term gene transfer due to their low immunogenicity and the possibility of generating rAAV vectors for stable, site-directed integration in the presence of the viral Rep proteins. 58 A major advantage of rAAV vectors in comparison with retrovirus vectors seems to be that they hold the potential for specific integration, at least in the presence of viral rep genes; rAAV vectors may be designed which contain sufficient rep to mediate specific integration. Moreover and in contrast to retroviral vec- tors, rAAV can transduce nondividing cells, 31 a function which is highly desirable for gene transfer into slowly dividing keratinocyte stem cells in vivo.
In conclusion, our results indicate that rAAV is a vector which holds great potential for gene transfer into primary human keratinocytes and keratinocyte stem cells. Further improvements in vector design, eg by using keratinocytespecific promoters for long-lasting transgene expression in vivo, or by using rAAV vectors containing all functions for mediating targeted integration of the transgene, will have to be developed before applying these vectors for skin gene therapy in vivo. 
